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Abstract
In rats with induced diabetes, Zinc and curcumin treatment showed a significant increase of catalase and a significant
decrease of glucose, lipid profile components and arylsulphatases activity compared to the untreated rats. We suggest
that dietary zinc and curcumin are promising protective agents for reducing the metabolic defect of diabetes.
Dear Editor;
Diabetes mellitus is a metabolic disease and the patho-
genesis of diabetes mellitus is implicated in the oxidative
stress and the generation of superoxide free radicals [1].
Various small molecules have been investigated for their
ability to ameliorate the diabetes. One such molecule is
curcumin (Cur) that has various health beneficial proper-
ties such as anti-inflammatory, anticarcinogenic, antiviral,
hypolipidemic and antiinfectious activities [2, 3]. The 2nd
molecule is the zinc (Zn) salt as an essential trace element.
The disturbances of its homeostasis seem to be associated
not only with diabetes, but also with others [4]. Recently,
it was reported that the lysosomal enzymes arylsulfatases
were significantly changed in experimental diabetes [5]. In
fact, the treatment of diabetes through food sources is
valuable around the world. Therefore, the present study is
undertaken to throw the light on the effect of Zn and Cur
on rats with experimental diabetes rats through studying
the effect on some lipid components and arylsulfatases as
important parameters, which are implicated in different
biological functions.
Male albino rats (120–160 g Bwt) were kept on a
balanced ration with water ad libitum for acclimatization.
Experimental diabetes was induced in overnight fasted
rats by intraperitoneal injection of a single dose of strepto-
zotocin (STZ) as 60 mg/kg Bwt. Rats with a serum glucose
level 218 mg/dl were considered as rats with diabetes. The
daily intake of Zn sulfate (100 mg/kg Bwt) and was
administrated orally in non-ionized water for 60 days. Cur
was suspended in saline and administrated orally by a
gavage 80 mg/kg Bwt Cur suspended daily in saline for
60 days. The rats were grouped randomly into eight
equal groups as the non-diabetic (control group), the
diabetic group, Zn non-diabetic group, Zn diabetic
group, Cur non-diabetic group, Cur diabetic group. The
last two groups that belong to Zn and Cur non-diabetic
and diabetic group received 50 and 40 mg/kg Bwt,
respectively as a daily for 60 days. The animals were
deprived of food overnight and sacrificed by decapitation.
Blood was collected from the eye canthus in tubes con-
taining potassium oxalate and sodium fluoride mixture
for estimation of plasma glucose (PG). Liver or pancreas
tissues were weighed, homogenized in10 mM Tris HCl
buffer, pH 7.0 and centrifuged at 4000 rpm for 15 min at
4 °C. The clear supernatant was obtained to measure the
activities of catalase [6], total protein [7] and both arylsulfa-
tase A (ASA) and arylsulfatase B (ASB) [8]. ASA and ASB
were fractionated by DEAE-cellulose chromatography as
described previously [8]. Insulin was assayed in the
homogenate of pancreas of all groups according to
instruction of Sigma-Aldrich insulin ELISA kit. Serum
total cholesterol (STC) was determined by cholesterol
oxidase and peroxidase [9]. Serum triacylglycerol (STG)
was determined as described previously [10]. Serum
LDL cholesterol (SLDL-c) and HDL cholesterol (SHDL-c)
levels were estimated as that described previously [11].
The obtained data during the experimental period were
statistically analyzed by the paired sample T-test (SPSS
version 16).
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A significant increase of plasma glucose was noted
after one and 60 days of STZ injection. Oral administration
of Zn, Cur and a combination of both showed a significant
effect on blood glucose levels (1.9 fold-increase). Similar
results were obtained by the effect of Cur, whereas an
increase of plasma sugar level of 4.7 folds in day one was
changed to be only 1.7 fold after 60 days of STZ-treatment.
Interestingly, on treating the rats by both Zn and Cur, the
noticed significant change of plasma sugar level in day one
was changed to be non-significant at 60 days of STZ-
treatment (Table 1). A reversed tendency to that of plasma
glucose was shown on measuring the insulin content of
pancreatic homogenate of animals from the different
groups. The rats with diabetes showed a significant
decrease (4.4 fold) in insulin compared to control (p <
0.001). Insulin level showed a non-significant change
after treatment with Zn and Cur. In addition, a signifi-
cant increase in the levels of serum total cholesterol
(STC) and triacylglycerol (STG) in the diabetic groups
was noticed in comparison to the non-diabetic groups.
Comparison of the diabetic groups versus the non-diabetic
groups showed a significant decrease in both SHDL-c and
SLDL-c levels in the diabetic groups and a significant
increase after treatment with Zn and Cur (Table 1). For
studying the effect of Zn and Cur on free radical pro-
duction, the activity of catalase was measured in both
plasma and liver. It presented a significant decrease in
diabetic compared to control rats. The effect of Zn and
Cur showed a significant increase of the specific activity
in serum and hepatic catalase compared to STZ-
induced diabetic rats (p < 0.05). Furthermore, there is a
significant increase in the specific activities of ASA and
ASB in both serum and liver in the rats of the diabetic
group compared to control (Table 2). Zn and Cur ad-
ministration decrease it significantly compared to the
diabetic group (p < 0.05). The significant increase of
catalase by Zn may be attributed to the competition of
Zn to both iron and copper for binding to cell membranes
and thus decreasing the production of OH- group [12].
This group in turn stimulates the peroxidation of mem-
brane lipids and hence the outflow of lysosomal constitu-
ents into cytosol [13]. The role of combination of both Zn
and Cur in diabetes showed a highly significant effective
result than the use of Zn or Cur alone. Taken together, we
suggest that Zn and Cur have an effective and a protective
role against the effect of diabetes—produced radicals on
lysosomes. Dietary Zn and Cur are promising protective
agents with a potential therapeutic approach to diabetes.
Table 1 Effect of Zn and curcumin on Lipid Profile distribution
Groups Plasma glucose
(PG, mg/dl)
Serum total cholesterol Serum triacylglycerol Serum LDL Serum HDL
Control 111.84 ± 2.56 50.25 ± 1.54 37.2 ± 1.73 63.75 ± 3.20 106.56 ± 3.04
Diabetic 381.81 ± 15.12** 137.02 ± 7.04** 635.63 ± 29.57** 50.71 ± 6.22** 41.79 ± 1.38**
Zn non-diabetic 73.61 ± 2.21* 32.67 ± 1.31* 37.9 ± 1.01 72.16 ± 3.40 79.24 ± 2.83*
Zn-treated diabetic 138.59 ± 7.81* 60.34 ± 3.67* 116.40 ± 3.54* 61.98 ± 4.44 99.04 ± 3.19
Cur non-diabetic 74.47 ± 2.99* 47.49 ± 1.45 23.95 ± 0.86* 56.70 ± 2.24 99.99 ± 2.19
Cur-treated diabetic 124.88 ± 4.36* 59.13 ± 3.07* 30.95 ± 1.39* 28.51 ± 3.60* 82.61 ± 3.40*
Zn and Cur non-diabetic 111.08 ± 4.39 47.15 ± 1.60 34.53 ± 1.66 58.09 ± 3.01 98.33 ± 2.40
Zn and Cur- treated diabetic 118.22 ± 4.90 51.47 ± 1.37 41.3 ± 2.30 38.88 ± 2.56* 82.89 ± 2.50*
The mean values of the serum level (mg/dl) of total cholesterol, triacylglycerol and the lipoproteins LDL and HDL in control, diabetic, Zn- and curcumin-treated
diabetic groups. The values are the means of 12 rats ± SE. Significance: *p < 0.05 and **p < 0.001 compared to control
Table 2 Effect of Zn and Cur on the specific activity of catalase (units/mg protein) and arylsulfatases ASA and ASB (nmol product/h/mg
protein)
Groups Serum Catalase(x 104) Hepatic Catalase(x104) Serum ASA Hepatic ASA Serum ASB Hepatic ASB
Control 1.09 ± 0.05 28.5 ± 1.4 12.01 ± 0.74 226.78 ± 10.25 23.28 ± 1.50 505.82 ± 23.03
Diabetic 0.49 ± 0.03** 4.4 ± 0.4** 25.58 ± 0.89** 555.36 ± 52.49** 34.24 ± 1.90* 627.79 ± 53.18**
Zn non-diabetic 1.00 ± 0.03 36.4 ± 2.8* 15.25 ± 0.81 268.04 ± 6.78* 34.69 ± 1.62* 531.61 ± 17.67*
Zn-treated diabetic 0.97 ± 0.03 34.1 ± 1.5* 9.53 ± 0.78* 214.66 ± 3.99* 21.42 ± 1.02 408.94 ± 15.37*
Cur non-diabetic 0.88 ± 0.03 36.9 ± 2.0* 14.86 ± 0.51 261.32 ± 8.47* 33.26 ± 2.08* 604.90 ± 11.17*
Cur-treated diabetic 1.03 ± 0.03 47.1 ± 1.9* 11.13 ± 0.66 260.33 ± 10.70* 32.87 ± 1.96* 431.83 ± 22.81*
Zn and Cur non-diabetic 1.01 ± 0.03 35.8 ± 1.5* 12.46 ± 0.23 174.60 ± 10.17* 31.10 ± 1.11* 501.37 ± 17.75
Zn and Cur-treated diabetic 1.00 ± 0.02 36.2 ± 2.5* 9.32 ± 0.40* 150.59 ± 11.39* 20.28 ± 1.14 333.67 ± 22.74*
The values are the means of 12 rats ± SE. Significance: *p < 0.05 and **p < 0.001 compared to control
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